Efficacy of the Nav1.7 blocker PF-05089771 in a randomised, placebo-controlled, double-blind clinical study in subjects with painful diabetic peripheral neuropathy

The effect of PF-05089771, a selective, peripherally restricted Nav1.7 sodium channel blocker on pain due to diabetic peripheral neuropathy was investigated in a randomised, placebo and active-controlled parallel group clinical trial (NCT02215252). A 1-week placebo-run in the period was followed by...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Pain (Amsterdam) Jg. 159; H. 8; S. 1465
Hauptverfasser:	McDonnell, Aoibhinn, Collins, Susie, Ali, Zahid, Iavarone, Laura, Surujbally, Raulin, Kirby, Simon, Butt, Richard P
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 01.08.2018
Schlagworte:	Adult Aged Diabetic Neuropathies - drug therapy Double-Blind Method Female Humans Male Middle Aged Neuralgia - drug therapy Phenyl Ethers - therapeutic use Pregabalin - therapeutic use Sodium Channel Blockers - therapeutic use Sulfonamides - therapeutic use Treatment Outcome
ISSN:	1872-6623, 1872-6623
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!